A phase II study of a 21 day continuous infusion schedule with epirubicin in advanced gastric cancer

Eur J Cancer Clin Oncol. 1989 Oct;25(10):1509-10. doi: 10.1016/0277-5379(89)90114-4.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Drug Evaluation
  • Epirubicin / administration & dosage*
  • Epirubicin / adverse effects
  • Epirubicin / therapeutic use
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Stomach Neoplasms / drug therapy*

Substances

  • Epirubicin